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Purpose. Women with ductal carcinoma in situ (DCIS) are often candidates for breast-conserving therapy, and one option for
radiation treatment is partial breast irradiation (PBI). This study evaluates the use of preoperative breast magnetic resonance
imaging (MRI) for PBI selection in DCIS patients. Methods. Between 2002 and 2009, 136 women with newly diagnosed DCIS
underwent a preoperative bilateral breast MRI at Mayo Clinic in Florida. One hundred seventeen women were deemed eligible
for PBI by the NSABP B-39 (National Surgical Adjuvant Breast and Bowel Project, Protocol B-39) inclusion criteria using physical
examination, mammogram, and/or ultrasound. MRIs were reviewed for their impact on patient eligibility, and ﬁndings were
pathologically conﬁrmed. Results. Of the 117 patients, 23 (20%) were found ineligible because of pathologically proven MRI
ﬁndings. MRI detected additional ipsilateral breast cancer in 21 (18%) patients. Of these women, 15 (13%) had more extensive
disease than originally noted before MRI, and 6 (5%) had multicentric disease in the ipsilateral breast. In addition, contralateral
breast cancer was detected in 4 (4%). Conclusions. Preoperative breast MRI altered the PBI recommendations for 20% of women.
Bilateral breast MRI should be an integral part of the preoperative evaluation of all patients with DCIS being considered for PBI.
1.Introduction
Ductal carcinoma in situ (DCIS) is a noninvasive breast
cancer and represents a complex pathologic condition in
which malignant epithelial cells arise and proliferate within
the ducts of the breast but do not invade the basement
membrane. According to the Surveillance Epidemiology and
End Results program (SEER), DCIS represents 14% of all
new breast cancer diagnoses in the United States [1].
Radiation therapy has historically been delivered to the
whole-breast after breast-conserving surgery. Adjuvant radi-
ation has been shown to improve local tumor control in
multipleprospective,randomizedclinicaltrials[2–4].Partial
breast irradiation (PBI) has been developed as a way to
deliver radiation directly to the tumor cavity of the breast
after breast-conserving surgery in lieu of whole-breast radi-
ation therapy. PBI can be delivered by multiple techniques,
including interstitial and intracavitary brachytherapy, intra-
operative radiotherapy, 3-dimensional (3D) conformal or
intensity-modulated radiation therapy,orprotontherapy. As
less breast tissue is being irradiated, the potential beneﬁts
include decreased acute toxicity to the breast and potential
decreased risk of late toxicity due to reduced radiation dose
to the surrounding tissue [5]. This reduced risk includes
the potential for decreased heart and lung toxicity [6].
An additional beneﬁt to patients is the decreased total2 International Journal of Surgical Oncology
treatment time. One commonly used course of PBI is 34
gray administered twice daily over 5 days, for a total of 10
fractions. Multiple fractionation schemes have been used,
including single-fraction treatments. For a select group of
patients, equivalent results have been reported for PBI versus
whole breast external beam radiotherapy [5, 7, 8].
TheNationalSurgicalAdjuvantBreastandBowelProject,
Protocol B-39 (NSABP B-39) is a prospective randomized
trial in which eligible women with early-stage breast cancer
are randomized to whole-breast radiation therapy versus
PBI. Speciﬁc eligibility criteria include tumor size ≤3cm,
≤3 positive lymph nodes, negative surgical margins, lack of
multicentric disease, and no contralateral breast cancer.
Bilateral breast magnetic resonance imaging (MRI) is
being used preoperatively with increasing frequency for
women with a new diagnosis of breast cancer. MRI has been
found to enhance ﬁndings in women when performed after
an initial clinical evaluation. Speciﬁcally in DCIS, MRI has
been prospectively shown to have a sensitivity of 92%, and
up to 98% for high-grade DCIS [9]. Multiple meta-analyses,
which include DCIS patients, have shown that MRI of the
ipsilateral breast detects additional disease in 16–20% of
women with newly diagnosed breast cancer [10, 11]. After
an initially negative evaluation, contralateral breast cancer
is detected by MRI in 3% to 6% of patients [11, 12]. These
results have been shown to alter surgical recommendations
[10–12].
This study evaluates the role of bilateral breast MRI in
determining eligibility for PBI based on the NSABP-B39
criteria in women with newly diagnosed DCIS.
2. Methods
ThisisaretrospectivereviewofwomendiagnosedwithDCIS
at Mayo Clinic in Florida between 2002 to 2009. All women
with a new diagnosis of DCIS who underwent a preoperative
bilateral breast MRI, regardless of their ultimate treatment,
were included in this study. Data collected on these women
included patient demographics, tumor characteristics, MRI
ﬁndings, and pathologic information. At Mayo Clinic in
Florida a preoperative bilateral breast MRI is recommended
as part of the evaluation of all women with a new diagnosis
of DCIS.
Women with DCIS were initially evaluated after the
standard clinical evaluation, which consisted of physical
examination, mammogram and/or ultrasound, and patho-
logic examination of a tissue biopsy. On the basis of the
initial clinical evaluation, each patient was determined to
be eligible or ineligible for PBI according to the NSABP
B-39 criteria. These criteria included tumor size ≤3cm
(including multifocal tumors to a maximum extent of
3cm); negative ﬁnal surgical margins; lack of multicentric
disease; no contralateral breast cancer. Multicentric disease
was deﬁned as additional disease >4cm from the original
tumor volume or disease within a diﬀerent breast quadrant.
Negative surgical margins are deﬁned as histologically free of
invasive and noninvasive tumor. Each patient was reviewed
again after the bilateral breast MRI, and the eligibility for
PBI was reassessed. All changes in PBI recommendations
made on the basis of MRI ﬁndings were conﬁrmed by ﬁnal
pathology. Tumor specimens were histologically evaluated,
and ﬁnal DCIS tumor size was determined by the maximum
histologic size. Patients were excluded from analysis if any of
these criteria were not met.
Breast MRI examinations were performed with the
patient in the prone position in a 1.5-tesla system (Avanto,
Espree, Sonata, or Symphony; Siemens Medical Solutions
USA Inc., Malvern, PA), using a dedicated surface breast
coil. The imaging sequence included an axial pre-contrast
3D fast low-angle shot (FLASH) sequence, T1-weighted,
3D, gradient-echo scans of both breasts, followed by a
sagittal T2-weighted turbo spin echo sequence of each
breast. Slice thickness was 3mm with a 0.6mm gap for all
images. The next series of images obtained included sagittal
3D ﬂash images of the breast with known cancer, then
imaging of the contralateral breast using the same technique,
both before and after a bolus of intravenous gadodiamide
(Omniscan; GE Healthcare, Waukesha, WI). If the patient’s
glomerular ﬁltration rate was higher than 60mL/min, 20mL
of gadobenate dimeglumine (MultiHance; Bracco Diagnos-
tics Inc,, Princeton, NJ) was used, and if the glomerular
ﬁltration rate was 30 to 60mL/min, 15mL of gadobenate
dimeglumine was administered. Patients with a glomerular
ﬁltration rate <30mL/min were not given a contrast agent
unless it was deemed absolutely necessary. Finally, bilateral
axial postcontrast 3D FLASH images were obtained using
the above-described parameters. Postprocessing included
subtraction of the pre- and postcontrast images and motion
correction, if necessary. MRIs were interpreted by board-
certiﬁed, subspecialist breast radiologists.
Patients who were deemed ineligible for PBI on the
basis of their bilateral breast MRI were categorized by
the reasons for their ineligibility. Speciﬁcally, women were
ineligible if the size of the tumor was described on MRI
(and pathologically proven) to be >3cm. Also ineligible
were patients with multifocal disease if the total tumor
extent was >3cm. These patients were classiﬁed as having
more extensive disease than determined by initial clinical
evaluation. Patients were also deemed ineligible if they were
diagnosedwithmulticentricbreastcancer,whichwasdeﬁned
as additional disease >4cm from the original tumor volume
ordiseasewithinadiﬀerentquadrant.Ifanycancerdiagnosis
was made in the contralateral breast, the patient also was
deemed ineligible. Results were conﬁrmed postsurgically
with the ﬁnal pathologic ﬁndings.
3. Statistics
Characteristics of patients, ﬁnal pathology results, and MRI
ﬁndingsweresummarizedbysamplemedian,25thpercentile
and 75th percentile for numerical variables, and by number
and percentage for categorical variables. For evaluation of
the primary aim, the proportion of DCIS patients whose
eligibility for PBI was altered by bilateral breast MRI ﬁndings
was estimated along with an exact binomial 95% conﬁdence
interval(CI).AllanalyseswereperformedusingSAS(version
9.2; SAS Institute Inc., Cary, NC).International Journal of Surgical Oncology 3
Table 1: Characteristics of 117 women with DCIS eligible for partial breast irradiation on the basis of an initial clinical evaluation, and of
the 23 women ultimately ineligible by MRI.
Variable Overall (N = 117) Ineligible based on MRI ﬁndings (N = 23)
No. (%)a
Age at diagnosis, y
31–40 3 (3%) 1 (4%)
41–50 20 (17%) 4 (17%)
51–60 31 (26%) 4 (17%)
61–70 25 (21%) 4 (17%)
71–80 30 (26%) 7 (30%)
81–91 8 (7%) 3 (13%)
Race
African American/Black 4 (3%) 1 (4%)
Asian 1 (1%) 0 (0%)
Caucasian 105 (90%) 21 (91%)
Hispanic 4 (3%) 1 (4%)
Other 3 (3%) 0 (0%)
Menopausal status
Post 89 (76%) 16 (70%)
Pre 28 (24%) 7 (30%)
No. of ﬁrst degree relatives with history of breast cancer
0 85 (73%) 14 (61%)
1 23 (20%) 6 (26%)
2-3 8 (7%) 2 (9%)
Unknown/not available 1 (1%) 1 (4%)
No. of relatives with history of breast cancer
0 71 (61%) 13 (57%)
1 27 (23%) 5 (22%)
2–4 18 (15%) 4 (17%)
Unknown/Not available 1 (1%) 1 (4%)
Dense breasts
No 32 (27%) 8 (35%)
Yes 79 (68%) 14 (61%)
Not reported/indeterminate 6 (5%) 1 (4%)
Detection method
Mammogram 105 (90%) 19 (83%)
Palpation 10 (9%) 3 (13%)
Other 2 (2%) 1 (4%)
Lumpectomy 68 (58%) 4 (17%)
No. of days from diagnosis to MRI 14 (0, 9, 23, 95) 12 (4, 8, 22, 34)
No. of days from diagnosis to surgery 38 (6, 27, 56, 813) 36 (21, 27, 57, 813)
aSample median (minimum, 1st quartile, 3rd quartile, maximum) is given for numerical variables, whereas n (%) is given for categorical variables.
4. Results
BetweenJanuary2002andJune2009,136womenwithnewly
diagnosed DCIS underwent a preoperative bilateral breast
MRI. Of these patients, 117 women (86%) were deemed eli-
gibleforPBIbasedontheNSABP-B39inclusioncriteriaafter
their initial clinical evaluation (i.e., a physical examination,
mammogram and/or ultrasound, and pathologic ﬁndings).
Characteristics of the 117 women (median age, 63; range 36–
90) who were initially eligible for PBI are summarized in
Table 1.
The pathologic results of the women who were recom-
mended to undergo a biopsy following MRI were evaluated.
In this cohort, 39% of women were recommended to have4 International Journal of Surgical Oncology
136 women with DCIS
117 eligible for PBI by initial evaluation
94 eligible for PBI after MRI 23 not eligible for PBI after MRI
4 with contralateral DCIS 21 with ipsilateral DCIS
15 more extensive disease
6 with multicentric disease
Figure 1
a biopsy either of the ipsilateral, contralateral, or bilateral
breasts. Of these patients, 37% were found to have additional
cancer.
MRI ﬁndings led to pathologically proven additional
diseasethatalteredtherecommendationsforPBIin23(20%;
95% CI: 13%–28%) of the 117 patients initially eligible for
PBI. MRI detected additional ipsilateral breast cancer in 21
(18%) patients. Of these women, 6 (5%) were diagnosed
with multicentric breast cancer. A total of 15 (13%) women
became ineligible for PBI due to more extensive disease as
determined by MRI and conﬁrmed by pathologic results.
Contralateralbreastcancerwasdetectedin4(4%)womenon
the basis of MRI results (Figure 1). Two women were found
to have both additional ipsilateral disease and contralateral
breast cancer.
Table 2 summarizes the ﬁnal pathologic ﬁndings of the
117 women initially deemed appropriate for PBI, and of the
23 women ultimately ineligible for PBI. Within this group, 8
(7%) patients were ultimately diagnosed with invasive breast
cancer.
A total of 15 patients had more extensive disease and the
mediantumorsizeinthisgroupwas4.0cm.Ofthe6patients
with multicentric disease, all additional tumors were smaller
than 1cm, and none of the patients had more than 2 tumors.
The 4 patients with contralateral tumors detected by MRI
were all smaller than 2cm.
5. Discussion
This study evaluates the use of bilateral breast MRI as a
diagnostic tool for women with newly diagnosed DCIS being
considered for PBI following breast conserving surgery. Of
117 patients deemed eligible for PBI after their initial clinical
evaluation, 20% became ineligible after MRI. Reasons for
ineligibility included additional ﬁndings of more extensive
disease, multicentric breast cancer, or contralateral breast
cancer.
Previous studies have focused on invasive cancers exclu-
sively, or in combination with non-invasive cancers. This
is the ﬁrst published study evaluating the role of MRI in
determining patient eligibility for PBI exclusively in patients
with DCIS. Previous studies, including our unpublished
data, show a change of 2–11% in PBI recommendations for
all breast cancer patients with a diagnosis of multicentric
disease after breast MRI [13–18]. Multifocality has also been
evaluated with a range of 4–7% change in PBI recommenda-
tions. Contralateral breast cancer diagnoses after MRI have
produced a 2–5% change in PBI recommendations [13–18].
This study found 5% of patients had a change in PBI
recommendations after MRI because of additional ﬁndings
of multicentric disease. This correlates with the published
data, as does the 4% change in PBI recommendations after
MRI for contralateral disease. This study did not examine
only multifocal disease, but it did evaluate multifocal disease
that led to ineligibility, as well as disease larger on MRI and
conﬁrmedbypathology,whichwasdeﬁnedasmoreextensive
disease. Therefore, the percentage of patients with altered
treatment recommendations because of more extensive dis-
ease (13%) was greater than that in published reports from
previous studies that evaluated multifocal disease alone.
These results for DCIS correlate well with those reported
in the medical literature on additional diagnoses made by
MRI. About one-ﬁfth (18% (21/117) of the patients had
altered eligibility either because of multicentric disease, mul-
tifocal disease, or larger disease within the ipsilateral breast,
which correlates well with the 16–20% additional ipsilateral
breast cancer diagnoses reported in the MRI literature [10,
11].The4%ofpatientsinwhomacontralateralbreastcancer
was diagnosed also correlates well [11, 12]. It is important to
note that of the 20% of patients ineligible for PBI, not all of
these women would have been excluded from consideration
of breast-conserving surgery.
All the patients included in this study underwent an
MRI on a 1.5-T machine. Plana et al. found a statisti-
cally signiﬁcant higher positive predictive value for breastInternational Journal of Surgical Oncology 5
Table 2: Final pathological results for 117 women eligible for partial breast irradiation on the basis of the initial clinical evaluation, and of
the 23 women ultimately ineligible by MRI.
Variable Overall (N = 117) Ineligible based on MRI ﬁndings (N = 23)
No. (%)a
Tumor size (cm)
Not available 8 (7%) 0 (0%)
0.1-1.0 61 (52%) 6 (26%)
1.1–2.0 28 (24%) 3 (13%)
2.1–3.0 9 (8%) 3 (13%)
>3.0 11 (9%) 11 (48%)
Number of tumors (>1) 14 (12%) 8 (35%)
EIC (positive) 6 (5%) 4 (17%)
Ts t a g e
Tis 109 (93%) 18 (78%)
T1a 6 (5%) 3 (13%)
T1b 1 (1%) 1 (4%)
T2 1 (1%) 1 (4%)
Ns t a g e
NX 44 (38%) 5 (22%)
N0 70 (60%) 16 (70%)
N1 3 (3%) 2 (9%)
Lymphovascular space invasion
No 113 (97%) 23 (100%)
Yes 1 (1%) 0 (0%)
Not reported/indeterminate 3 (3%) 0 (0%)
Lobular features 1 (1%) 1 (4%)
Grade
Low 26 (22%) 10 (43%)
Intermediate 25 (21%) 2 (9%)
High 66 (56%) 11 (48%)
ER
Negative 25 (21%) 8 (35%)
Positive 89 (76%) 14 (61%)
Not tested/not available 3 (3%) 1 (4%)
PR
Negative 36 (31%) 10 (43%)
Positive 77 (66%) 12 (52%)
Not tested/not available 4 (3%) 1 (4%)
EIC: extensive intraductal component. ER: estrogen receptor. PR: progestin receptor.
aValues are numbers (percentage).
MRI when using ≥1.5 T MRI [11]. MRI has also been
found to have a high sensitivity for DCIS as reported by
Kuhl et al. with 1.5T machines [9]. Some previous studies
used 1-T MRI, which may have led to decreased detection of
additional disease.
This study is limited as a retrospective review. It is,
however, the ﬁrst study conducted to date that evaluates the
role of MRI in determining appropriate candidacy for PBI
for women with DCIS. It is also a more thorough evaluation
about the utility of MRI for not only evaluating multicentric
and contralateral breast cancers but also for evaluating more
extensive disease, including tumors >3cm and multifocal
disease that extends >3cm within the breast. By including
more extensive disease, an additional 13% of women were
identiﬁed as being ineligible for PBI after breast MRI than by
evaluation of multicentricity and contralateral disease alone.
6. Conclusions
These results show that 20% of women with DCIS became
ineligible for PBI after a bilateral breast MRI. Recognition6 International Journal of Surgical Oncology
of PBI ineligibility prior to surgery can improve clinical
planning,includingtheavoidanceofunnecessaryprocedures
associated with brachytherapy and intraoperative radiation
therapy. Bilateral breast MRI should be an integral part of
thepreoperativeevaluationofallpatients withDCISwhoare
being considered for PBI.
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